Medicenna Therapeutics Corp. Common Shares
MDNA
MDNA was delisted on the 1st of November, 2023.
31 hedge funds and large institutions have $22.9M invested in Medicenna Therapeutics Corp. Common Shares in 2021 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.
333% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 3
111% more capital invested
Capital invested by funds: $10.8M → $22.9M (+$12.1M)
48% more funds holding
Funds holding: 21 → 31 (+10)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
5.74% more ownership
Funds ownership: 4.72% → 10.46% (+5.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
+$3.92M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$3.42M |
| 3 |
Janus Henderson Group
London,
|
+$2.16M |
| 4 |
IIM
Intact Investment Management
Montreal,
Quebec, Canada
|
+$1.57M |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$806K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$874K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$147K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$111K |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$60K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$48.9K |
MDNA Hedge Fund Activity: Q1 2021 in Review
31 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Medicenna Therapeutics Corp. Common Shares (MDNA) for Q1 2021, worth a combined $22.9M — up 111% from $10.8M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new MDNA positions and 3 closed out — a net gain of 10 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Board of Trustees of The Leland Stanford Junior University, opening a new position worth an estimated $3.92M. The largest seller was Soleus Capital Management, exiting entirely with an estimated $874K sold.
- 31 institutional investors held Medicenna Therapeutics Corp. Common Shares (MDNA) as of Q1 2021, up from 21 in Q4 2020.
- Funds reported $22.9M of Medicenna Therapeutics Corp. Common Shares stock for Q1 2021, up 111% quarter-over-quarter.
- 13 funds opened new Medicenna Therapeutics Corp. Common Shares positions in Q1 2021 and 3 closed out, a net change of +10 holders.
- The largest Medicenna Therapeutics Corp. Common Shares buyer in Q1 2021 was Board of Trustees of The Leland Stanford Junior University, an estimated $3.92M added.
- The largest Medicenna Therapeutics Corp. Common Shares seller in Q1 2021 was Soleus Capital Management, an estimated $874K sold.
Based on aggregated 13F filings for Q1 2021.